Evaluating the effectiveness and safety of JAK inhibitors for alopecia areata
Official title: Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT06573593 · Data updated 2026-11-12
This study is testing how well and safely JAK inhibitors work for kids and teens with alopecia areata who have been using them for at least three months.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years to 80 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Drugs / interventions | tofacitinib, baricitinib, ritlecitinib, abrocitinib, upadacitinib, ifidancitinib |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | July 29, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 27, 2024 |
| Trial ID | NCT06573593 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged 2 to 18 years diagnosed with alopecia areata and treated with JAK inhibitors for more than three months.
✕Probably not a fit
Patients who have received hair implants or have other forms of alopecia or diseases that induce alopecia may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the real-world effectiveness and safety of various Janus Kinase inhibitors (JAKi) in patients with alopecia areata (AA). It will gather data on patients aged 2 to 18 who have been treated with JAKi for over three months, focusing on their baseline disease characteristics and profiles that indicate suitability for JAKi therapy. The study will provide valuable clinical evidence to help clinicians and patients make informed decisions regarding individualized treatment plans for AA.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the most effective JAK inhibitors for treating alopecia areata, leading to better patient outcomes.
How similar studies have gone: While the use of JAK inhibitors in alopecia areata is a relatively new approach, preliminary studies have shown promising results, indicating potential for success in this area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with alopecia areata between 2 to 18 years old * Patients diagnosed with alopecia areata according to AA guideline * AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months Exclusion Criteria: * Patients had previously received hair implants * Other alopecia * Other diseases may induce alopecia including psoriasis, lichen planus, et al. * Unable to estimate SALT score at baseline or at follow-up * Patients are participating in other clinical trials
Where it's running
-
Second Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Xianjie Wu, Ph.D — Second Affiliated Hospital, Zhejiang University, School of Medicine
- Study coordinator: Ru Dai, MD
- Email: dairu@zju.edu.cn
- Phone: 15982215914
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Which works better for patchy hair loss: steroid injections or microneedling with steroid cream?
This trial tests whether injecting triamcinolone into the skin or using microneedling with topical triamcinolone helps people with alopecia areata regrow hair more effectively.
-
Red Ultraviolet Hair Imaging and Hair Growth in Alopecia Areata
This observational study checks if red fluorescence seen with UV hair imaging relates to disease features and how well hair regrows after standard intralesional corticosteroid treatment in adults with limited plaque-type alopecia areata.
-
VC005 tablets in teens with severe alopecia areata
This Phase 1 study tests VC005 tablets in adolescents with severe alopecia areata to see how the drug behaves in the body, whether it is safe, and if there are signs of benefit.
-
VC005 tablets in severe alopecia areata
This study tests whether VC005 tablets work better than a placebo for adults with severe alopecia areata.
-
Ritlecitinib for patchy hair loss in teens and adults with alopecia areata
This study tests whether ritlecitinib can help people 12 and older with patchy alopecia areata who have had symptoms for 6 months to 10 years.
-
Alopecia Areata: looking at ferroptosis markers in blood
This study tests whether levels of GPX4 and MDA in blood differ between people with alopecia areata and healthy controls.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.